To investigate the potency and efficacy of ICE® constructs to mediate destruction of target tumor cells, EpCAM-specific ICE® constructs, anti-EpCAM IgG1 control antibodies and the CD30-specific ICE® were subjected to standard 4 h calcein-release cytotoxicity assays using EpCAM+/CD30− tumor cell lines (HCC-1954, Detroit 562, and HCC-1187) and the EpCAM−/CD30+ KARPAS-299 cell line. The gene discussed is TNFRSF8; the disease is hepatocellular carcinoma.